Skip to Content

Clinical Highlights

Aesthetics

Announcing Sakura 3 Results

Disclaimer: DaxibotulinumtoxinA for Injection is currently an investigational product and not approved by FDA. Anticipated approval in 2020.

More than 73.5% subjects in Sakura 1 and 2 achieved a two-grade improvement in glabellar lines as assessed by with the patient and the investigator at week 4 after treatment1

Load More

Disclaimers

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA. Anticipated approval in 2020
* DaxibotulinumtoxinA for Injection was formerly known as RT002.

References

  1. Carruthers JD, et al. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45–58. doi:10.1097/PRS.0000000000006327
Back to top